---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062234"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:57:15.246586+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aptevo enters warrant inducement to raise up to $3.4M, issues new warrants at $0.233

## Summary
- Existing warrant holders agree to exercise up to 16,013,034 shares at $0.233 per share for up to ~$3.4M gross proceeds.
- New Series A and B warrants issued for 200% of exercised shares, with exercise price $0.233; 50% immediately exercisable.
- Proceeds to fund clinical development and working capital; A.G.P./Alliance Global Partners serves as financial advisor (7% fee).
- New warrants subject to beneficial ownership limitations (4.99% or 9.99%); registration statement for resale to be filed by Nov 27, 2023.

## SEC filing metadata
- accession: 0000950170-23-062234
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017023062234/0000950170-23-062234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017023062234/apvo-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062234
- JSON: https://secwatch.observer/filing/0000950170-23-062234.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062234.txt

## Key facts
- Material Agreements
  Aptevo Therapeutics Inc. entered into Inducement Agreement with certain holders of existing Series A Common Stock Purchase Warrants and Series B Common Stock Purchase Warrants valued at up to approximately $3.4 million (effective 2023-11-09).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain holders of existing Series A Common Stock Purchase Warrants and Series B Common Stock Purchase Warrants
  - Value: up to approximately $3.4 million
  - Effective: 2023-11-09
  source text: On November 9, 2023, Aptevo Therapeutics Inc. (the “Company”) entered into a warrant inducement agreement (the “Inducement Agreement”) with certain holders (the “Holders”) of the Company’s existing Series A Common Stock Purchase Warrants (“Existing Series A Warrants”) and Series B Common Stock Purchase Warrants (“Existing Series B Warrants” and together, the “Existing Warrants”) to purchase shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671584/000095017023062234/0000950170-23-062234-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.